外周血单个核细胞
人性化鼠标
免疫疗法
癌症免疫疗法
肺癌
外周血
医学
免疫学
PD-L1
癌症研究
免疫系统
生物
肿瘤科
生物化学
体外
作者
Shouheng Lin,Guohua Huang,Lin Cheng,Zhen Li,Yiren Xiao,Qiuhua Deng,Yuchuan Jiang,Baiheng Li,Simiao Lin,Suna Wang,Qiting Wu,Huihui Yao,Su Mei Cao,Yang Li,Pentao Liu,Wei Wei,Duanqing Pei,Yao Yao,Zhesheng Wen,Xuchao Zhang
出处
期刊:mAbs
[Landes Bioscience]
日期:2018-10-02
卷期号:10 (8): 1301-1311
被引量:94
标识
DOI:10.1080/19420862.2018.1518948
摘要
Animal models used to evaluate efficacies of immune checkpoint inhibitors are insufficient or inaccurate. We thus examined two xenograft models used for this purpose, with the aim of optimizing them. One method involves the use of peripheral blood mononuclear cells and cell line-derived xenografts (PBMCs-CDX model). For this model, we implanted human lung cancer cells into NOD-scid-IL2Rg-/- (NSI) mice, followed by injection of human PBMCs. The second method involves the use of hematopoietic stem and progenitor cells and CDX (HSPCs-CDX model). For this model, we first reconstituted the human immune system by transferring human CD34+ hematopoietic stem and progenitor cells (HSPCs-derived humanized model) and then transplanted human lung cancer cells. We found that the PBMCs-CDX model was more accurate in evaluating PD-L1/PD-1 targeted immunotherapies. In addition, it took only four weeks with the PBMCs-CDX model for efficacy evaluation, compared to 10-14 weeks with the HSPCs-CDX model. We then further established PBMCs-derived patient-derived xenografts (PDX) models, including an auto-PBMCs-PDX model using cancer and T cells from the same tumor, and applied them to assess the antitumor efficacies of anti-PD-L1 antibodies. We demonstrated that this PBMCs-derived PDX model was an invaluable tool to study the efficacies of PD-L1/PD-1 targeted cancer immunotherapies. Overall, we found our PBMCs-derived models to be excellent preclinical models for studying immune checkpoint inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI